Evidence map›Paper›PMID 31695052›Full record

ArticleScientific reports2019

Chemical activation of divergent protein tyrosine phosphatase domains with cyanine-based biarsenicals.

Bailey A Plaman, Wai Cheung Chan, Anthony C Bishop

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bailey A PlamanAmherst College, Department of Chemistry, Amherst, Massachusetts, 01002, USA.
Wai Cheung ChanAmherst College, Department of Chemistry, Amherst, Massachusetts, 01002, USA.ORCID http://orcid.org/0000-0001-8413-5401
Anthony C BishopAmherst College, Department of Chemistry, Amherst, Massachusetts, 01002, USA. acbishop@amherst.edu.ORCID http://orcid.org/0000-0001-8394-280X

Funding

Target-specific inhibition and activation of protein tyrosine phosphatasesR15GM071388 · NIGMS · AMHERST COLLEGE · PI BISHOP, ANTHONY C · 2005 to 2021
$1.6M
NIGMS NIH HHS R15 GM071388
6 · The paper itself

Abstract

Strategies for the direct chemical activation of specific signaling proteins could provide powerful tools for interrogating cellular signal transduction. However, targeted protein activation is chemically challenging, and few broadly applicable activation strategies for signaling enzymes have been developed. Here we report that classical protein tyrosine phosphatase (PTP) domains from multiple subfamilies can be systematically sensitized to target-specific activation by the cyanine-based biarsenical compounds AsCy3 and AsCy5. Engineering of the activatable PTPs (actPTPs) is achieved by the introduction of three cysteine residues within a conserved loop of the PTP domain, and the positions of the sensitizing mutations are readily identifiable from primary sequence alignments. In the current study we have generated and characterized actPTP domains from three different subfamilies of both receptor and non-receptor PTPs. Biarsenical-induced stimulation of the actPTPs is rapid and dose-dependent, and is operative with both purified enzymes and complex proteomic mixtures. Our results suggest that a substantial fraction of the classical PTP family will be compatible with the act-engineering approach, which provides a novel chemical-biological tool for the control of PTP activity and the study of PTP function.

Indexed as

ArsenicalsCysteineDose-Response Relationship, DrugEnzyme ActivationHumansMutagenesis, Site-DirectedPhosphopeptidesPoint MutationProtein DomainsProtein Tyrosine PhosphatasesProteomeReceptor-Like Protein Tyrosine PhosphatasesRecombinant ProteinsSequence AlignmentArsenicalsAsCy3 compoundCysteinePhosphopeptidesProtein Tyrosine PhosphatasesProteomeReceptor-Like Protein Tyrosine PhosphatasesRecombinant Proteins

Identifiers

PMID31695052
PMCPMC6834593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.